Alexion Pharmaceuticals Proprietà degli esecutivi
Cos'è Proprietà degli esecutivi di Alexion Pharmaceuticals?
Proprietà degli esecutivi di Alexion Pharmaceuticals Inc. è 0.34%
Qual è la definizione di Proprietà degli esecutivi?
La proprietà degli esecutivi (Insider Ownership) è calcolata come il numero totale di azioni possedute dagli esecutivi (azionisti che detengono più del 5% della società o un funzionario o direttore della società) diviso per il totale delle Azioni in circolazione.
A high value of insider ownership means that those working for the company have a large stake in the success of the company. This is sometimes seen as a sign that those running the company will work hard to ensure its success or believe the company's stock price will rise.
A change in insider ownership may come from exercise of option, stock grant and buying or selling of company shares. A purchase of company share signifies a confidence in the company's future performance by people who know the company best. Therefore, Net Insider buying is also an important indicator for investors.
Proprietà degli esecutivi di aziende nel Health Care settore su NASDAQ rispetto a Alexion Pharmaceuticals
Cosa fa Alexion Pharmaceuticals?
Alexion is a global biopharmaceutical company focused on serving patients and families affected by rare diseases and devastating conditions through the discovery, development and commercialization of life-changing medicines. As a leader in rare diseases for more than 25 years, Alexion has developed and commercializes two approved complement inhibitors to treat patients with paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS), as well as the first and only approved complement inhibitor to treat anti-acetylcholine receptor (AchR) antibody-positive generalized myasthenia gravis (gMG) and neuromyelitis optica spectrum disorder (NMOSD). Alexion also has two highly innovative enzyme replacement therapies for patients with life-threatening and ultra-rare metabolic disorders, hypophosphatasia (HPP) and lysosomal acid lipase deficiency (LAL-D) as well as the first and only approved Factor Xa inhibitor reversal agent. In addition, the company is developing several mid-to-late-stage therapies, including a copper-binding agent for Wilson disease, an anti-neonatal Fc receptor (FcRn) antibody for rare Immunoglobulin G (IgG)-mediated diseases and an oral Factor D inhibitor as well as several early-stage therapies, including one for light chain (AL) amyloidosis, a second oral Factor D inhibitor and a third complement inhibitor. Alexion focuses its research efforts on novel molecules and targets in the complement cascade and its development efforts on hematology, nephrology, neurology, metabolic disorders, cardiology, ophthalmology and acute care. Headquartered in Boston, Massachusetts, Alexion has offices around the globe and serves patients in more than 50 countries.
Aziende con proprietà degli esecutivi simili a Alexion Pharmaceuticals
- International Paper ha Proprietà degli esecutivi di 0.34%
- Æterna Zentaris ha Proprietà degli esecutivi di 0.34%
- COSCIENS Biopharma ha Proprietà degli esecutivi di 0.34%
- Toromont Industries ha Proprietà degli esecutivi di 0.34%
- Noble Corp Plc ha Proprietà degli esecutivi di 0.34%
- China Environmental Investment ha Proprietà degli esecutivi di 0.34%
- Alexion Pharmaceuticals ha Proprietà degli esecutivi di 0.34%
- The UNITE Plc ha Proprietà degli esecutivi di 0.34%
- Lloyds Banking Plc ha Proprietà degli esecutivi di 0.34%
- Mobeus Income & Growth VCT plc ha Proprietà degli esecutivi di 0.34%
- Apartment Income REIT ha Proprietà degli esecutivi di 0.34%
- CVS Health Corp ha Proprietà degli esecutivi di 0.34%
- CVS Health ha Proprietà degli esecutivi di 0.34%